Using anonymized electronic medical records, CDC staff looked at prescriptions given to obese adolescents for obesity drugs
This included existing drugs, like setmelanotide, as well as newer GLP-1 inhibitors licensed specifically for obesity
This included existing drugs, like setmelanotide, as well as newer GLP-1 inhibitors licensed specifically for obesity
June 5, 2025 at 11:42 PM
Using anonymized electronic medical records, CDC staff looked at prescriptions given to obese adolescents for obesity drugs
This included existing drugs, like setmelanotide, as well as newer GLP-1 inhibitors licensed specifically for obesity
This included existing drugs, like setmelanotide, as well as newer GLP-1 inhibitors licensed specifically for obesity
P3 data assessing the efficacy and safety of setmelanotide once daily in acquired hypothalamic obesity over 52 weeks www.nejm.org/doi/full/10....
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity | NEJM
A phase 2 trial of setmelanotide, a melanocortin-4 receptor agonist, showed substantial
weight loss in patients with acquired hypothalamic obesity, but additional data are
needed. We conducted a ph...
www.nejm.org
July 8, 2026 at 9:10 PM
P3 data assessing the efficacy and safety of setmelanotide once daily in acquired hypothalamic obesity over 52 weeks www.nejm.org/doi/full/10....
It's really something to see progress for conditions like hypothalamic obesity, which can happen after brain tumor care. A new oral drug, setmelanotide, helps by targeting the brain's appetite control. A Phase III trial showed it cut extreme hunger, reducing scores by -2.
Setmelanotide Significantly Reduces BMI and Hunger in Pediatric and Adult Patients With Acquired Hyp
A Phase III clinical trial (TRANSCEND) has shown that setmelanotide, an oral medication, significantly reduced body mass index (BMI) and extreme hunger in children and adults who developed hypothalami
ascopost.com
July 15, 2026 at 8:05 AM
It's really something to see progress for conditions like hypothalamic obesity, which can happen after brain tumor care. A new oral drug, setmelanotide, helps by targeting the brain's appetite control. A Phase III trial showed it cut extreme hunger, reducing scores by -2.
A new study in the New England Journal of Medicine shows setmelanotide, an MC4R agonist, can restore appetite control and achieve weight loss in patients…
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #Obesitytreatment
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #O…
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #Obesitytreatment
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #O…
New drug for hypothalamic obesity shows promise
A new study in the New England Journal of Medicine shows setmelanotide, an MC4R agonist, can restore appetite control and achieve weight loss in patients…
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #Obesitytreatment
news.gmj.ge
September 25, 2026 at 1:26 PM
A new study in the New England Journal of Medicine shows setmelanotide, an MC4R agonist, can restore appetite control and achieve weight loss in patients…
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #Obesitytreatment
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #O…
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #Obesitytreatment
#Appetiteregulation #Hypothalamicobesity #MC4Ragonist #NEJM #O…
Heterozygous mutations in leptin receptor gene (LEPR) do not cause obesity. The finding goes against the rationale for a recent clinical trial that test setmelanotide for obesity treatment in heterozygous carriers of LEPR variants.
Delplanque et al. AJHG
www.sciencedirect.com/science/arti...
Delplanque et al. AJHG
www.sciencedirect.com/science/arti...
November 29, 2024 at 2:20 AM
Heterozygous mutations in leptin receptor gene (LEPR) do not cause obesity. The finding goes against the rationale for a recent clinical trial that test setmelanotide for obesity treatment in heterozygous carriers of LEPR variants.
Delplanque et al. AJHG
www.sciencedirect.com/science/arti...
Delplanque et al. AJHG
www.sciencedirect.com/science/arti...
Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Read the full TRANSCEND trial results: https://nej.md/3Rm9E3L
July 13, 2026 at 4:02 AM
Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Read the full TRANSCEND trial results: https://nej.md/3Rm9E3L
It seems a lot of anti vaxxers are happy to consume Bupropion-naltrexone (Contrave)
Liraglutide (Saxenda)
Orlistat (Xenical, Alli)
Phentermine-topiramate (Qsymia)
Semaglutide (Wegovy)
Setmelanotide (Imcivree)
Liraglutide (Saxenda)
Orlistat (Xenical, Alli)
Phentermine-topiramate (Qsymia)
Semaglutide (Wegovy)
Setmelanotide (Imcivree)
January 13, 2025 at 5:25 AM
It seems a lot of anti vaxxers are happy to consume Bupropion-naltrexone (Contrave)
Liraglutide (Saxenda)
Orlistat (Xenical, Alli)
Phentermine-topiramate (Qsymia)
Semaglutide (Wegovy)
Setmelanotide (Imcivree)
Liraglutide (Saxenda)
Orlistat (Xenical, Alli)
Phentermine-topiramate (Qsymia)
Semaglutide (Wegovy)
Setmelanotide (Imcivree)
In a Phase 3 trial for acquired hypothalamic obesity, a rare brain injury causing rapid weight gain, patients on setmelanotide saw an average 16.5% BMI drop vs placebo's 3.3% increase. The FDA just approved this, bringing vital options to those who've struggled.
FDA Approves New Treatment for Rare Brain Injury-Induced Obesity
The U.S. Food and Drug Administration (FDA) has approved setmelanotide as a new treatment for acquired hypothalamic obesity, a rare condition causing rapid, uncontrollable weight gain due to brain dam
news.feinberg.northwestern.edu
July 16, 2026 at 8:05 PM
In a Phase 3 trial for acquired hypothalamic obesity, a rare brain injury causing rapid weight gain, patients on setmelanotide saw an average 16.5% BMI drop vs placebo's 3.3% increase. The FDA just approved this, bringing vital options to those who've struggled.
TRANSCEND trial: Approved treatments are lacking for acquired hypothalamic obesity. New research findings on the efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, are summarized in a Quick Take video: https://nej.md/4eVGFg9
July 13, 2026 at 11:02 AM
TRANSCEND trial: Approved treatments are lacking for acquired hypothalamic obesity. New research findings on the efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, are summarized in a Quick Take video: https://nej.md/4eVGFg9
Proof-of-concept for setmelanotide as a treatment for sleep disordered breathing—
Vsevolod Polotsky & team find the melanocortin 4 receptor agonist stimulates breathing and decreases apnea during sleep in diet-induced obese mice via parafacial neurons.: buff.ly/10cCrKI
Vsevolod Polotsky & team find the melanocortin 4 receptor agonist stimulates breathing and decreases apnea during sleep in diet-induced obese mice via parafacial neurons.: buff.ly/10cCrKI
June 18, 2025 at 1:20 PM
Proof-of-concept for setmelanotide as a treatment for sleep disordered breathing—
Vsevolod Polotsky & team find the melanocortin 4 receptor agonist stimulates breathing and decreases apnea during sleep in diet-induced obese mice via parafacial neurons.: buff.ly/10cCrKI
Vsevolod Polotsky & team find the melanocortin 4 receptor agonist stimulates breathing and decreases apnea during sleep in diet-induced obese mice via parafacial neurons.: buff.ly/10cCrKI
Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Full results of the TRANSCEND trial: https://nej.md/3Rm9E3L
July 8, 2026 at 9:35 PM
Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks. Full results of the TRANSCEND trial: https://nej.md/3Rm9E3L
Humble case report from prior Ross lab member Katie Kuk, who is now a psych intern, on the PREVIOUSLY UNHEARD OF improvement in cognitive function in a patient with a rare developmental disorder after starting a med to treat obesity. www.frontiersin.org/journals/end...
Frontiers | Case Report: Improvement in cognitive functioning following setmelanotide initiation in a patient with Bardet-Biedl syndrome
Bardet-Biedl syndrome (BBS) is a rare genetic condition that results from mutations in a variety of genes crucial for ciliary transport. Consequently, patien...
www.frontiersin.org
September 19, 2025 at 2:11 PM
Humble case report from prior Ross lab member Katie Kuk, who is now a psych intern, on the PREVIOUSLY UNHEARD OF improvement in cognitive function in a patient with a rare developmental disorder after starting a med to treat obesity. www.frontiersin.org/journals/end...
More #weightloss data supporting the utility of Setmelanotide, here in the context of #obesity secondary to brain injury endpts.com/rhythm-touts...
Rhythm touts Phase 3 win for rare obesity drug in people with brain damage
Rhythm Pharmaceuticals' Imcivree shows promise in treating obesity from brain damage, reducing BMI by 16.5% in Phase 3 trial; regulatory filings planned for 2025.
endpts.com
April 7, 2025 at 8:21 PM
More #weightloss data supporting the utility of Setmelanotide, here in the context of #obesity secondary to brain injury endpts.com/rhythm-touts...
BRIEF REPORT Real-life Experience on Efficacy and Safety of #Setmelanotide Treatment in Prepubertal Children by Ahmet Kahveci et al
EJE Volume 192, Issue 2, February 2025
👉 doi.org/10.1093/ejen...
ESE Members free access via 👉 my.ese-hormones.org
#gonadotropin
EJE Volume 192, Issue 2, February 2025
👉 doi.org/10.1093/ejen...
ESE Members free access via 👉 my.ese-hormones.org
#gonadotropin
Real-life experience on efficacy and safety of setmelanotide treatment in prepubertal children
Abstract. Monogenic obesity, characterized by severe, early-onset obesity due to single-gene defects, often resists traditional weight management strategie
doi.org
March 11, 2025 at 5:51 PM
BRIEF REPORT Real-life Experience on Efficacy and Safety of #Setmelanotide Treatment in Prepubertal Children by Ahmet Kahveci et al
EJE Volume 192, Issue 2, February 2025
👉 doi.org/10.1093/ejen...
ESE Members free access via 👉 my.ese-hormones.org
#gonadotropin
EJE Volume 192, Issue 2, February 2025
👉 doi.org/10.1093/ejen...
ESE Members free access via 👉 my.ese-hormones.org
#gonadotropin
Setmelanotide fails to lower BMI in patients with heterozygous genes tied to obesity
April 7, 2026 at 12:28 PM
Setmelanotide fails to lower BMI in patients with heterozygous genes tied to obesity
From #ENDO2025: #Setmelanotide was associated with significant #WeightReduction among adult and pediatric patients with acquired #HypothalamicObesity.
@endocrinesociety.bsky.social @ucsdhealth.bsky.social @themaximacenter.bsky.social @sickkidsto.bsky.social @childrensphila.bsky.social
@endocrinesociety.bsky.social @ucsdhealth.bsky.social @themaximacenter.bsky.social @sickkidsto.bsky.social @childrensphila.bsky.social
Setmelanotide Safe, Efficacious in Treating Acquired Hypothalamic Obesity
Setmelanotide was associated with significant weight reduction among patients aged 4 years and older with acquired hypothalamic obesity.
www.endocrinologyadvisor.com
July 14, 2025 at 7:03 PM
From #ENDO2025: #Setmelanotide was associated with significant #WeightReduction among adult and pediatric patients with acquired #HypothalamicObesity.
@endocrinesociety.bsky.social @ucsdhealth.bsky.social @themaximacenter.bsky.social @sickkidsto.bsky.social @childrensphila.bsky.social
@endocrinesociety.bsky.social @ucsdhealth.bsky.social @themaximacenter.bsky.social @sickkidsto.bsky.social @childrensphila.bsky.social
New in NEJM:
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
July 9, 2026 at 1:00 PM
New in NEJM:
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2 trials)
Setmelanotide for Acquired Hypothalamic Obesity (TRANSCEND)
Ensartinib after Resection in ALK-Positive NSCLC (ELEVATE)
Explore the issue: https://nej.md/current-issue
CASE REPORT: Early setmelanotide in LEPR-deficient twins: psychomotor and metabolic outcome by Patricia Pigeon-Kherchiche et al
Obesity and Endocrinology, Volume 1, Issue 2, July 2025
Open access 👉 doi.org/10.1093/oben...
#obesity #setmelanotide #hyperphagia
Obesity and Endocrinology, Volume 1, Issue 2, July 2025
Open access 👉 doi.org/10.1093/oben...
#obesity #setmelanotide #hyperphagia
March 2, 2026 at 4:58 PM
CASE REPORT: Early setmelanotide in LEPR-deficient twins: psychomotor and metabolic outcome by Patricia Pigeon-Kherchiche et al
Obesity and Endocrinology, Volume 1, Issue 2, July 2025
Open access 👉 doi.org/10.1093/oben...
#obesity #setmelanotide #hyperphagia
Obesity and Endocrinology, Volume 1, Issue 2, July 2025
Open access 👉 doi.org/10.1093/oben...
#obesity #setmelanotide #hyperphagia
An update on new clinical trial data for setmelanotide in rare genetic forms of #obesity ir.rhythmtx.com/news-release...
March 17, 2026 at 5:13 PM
An update on new clinical trial data for setmelanotide in rare genetic forms of #obesity ir.rhythmtx.com/news-release...
#RYTM Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
https://www.stocktitan.net/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-5xykltomhmg2.html
https://www.stocktitan.net/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-5xykltomhmg2.html
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older. Approval was based on the Phase 3 TRANSCEND trial showing a -18.4% placebo-adjusted BMI reduction.IMCIVREE is available immediately in the U.S.; Rhythm estimates ~10,000 people in the U.S. live with acquired HO. The company will host a conference call today at 7:00 p.m. ET.
www.stocktitan.net
March 19, 2026 at 10:30 PM
#RYTM Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
https://www.stocktitan.net/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-5xykltomhmg2.html
https://www.stocktitan.net/news/RYTM/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-5xykltomhmg2.html
Rhythm Pharmaceuticals (#$RYTM) presents new setmelanotide data at ESPE 2026: a French real-world study (n=30) showed BMI reductions of 9-13.4% through 18 months. A Phase 3 post-hoc analysis showed added cardiometabolic benefits vs placebo.
prismmarketview.com/rhythm-highl...
prismmarketview.com/rhythm-highl...
September 10, 2026 at 5:14 PM
Rhythm Pharmaceuticals (#$RYTM) presents new setmelanotide data at ESPE 2026: a French real-world study (n=30) showed BMI reductions of 9-13.4% through 18 months. A Phase 3 post-hoc analysis showed added cardiometabolic benefits vs placebo.
prismmarketview.com/rhythm-highl...
prismmarketview.com/rhythm-highl...
Just In: ( NASDAQ: #RYTM ) Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE (setmelanotide) in Patients as Young as 2 years old
#StockMarket #News
#StockMarket #News
August 26, 2024 at 4:55 PM
@ims-mrl.bsky.social researchers are exploring how weight loss-through diet, precision medication, or surgery-can improve long-term health outcomes in children and adults. The Farooqi lab and colleagues showed setmelanotide can manage obesity in patients < 6 years old.
doi.org/10.1016/S221...
doi.org/10.1016/S221...
March 4, 2025 at 4:21 PM
@ims-mrl.bsky.social researchers are exploring how weight loss-through diet, precision medication, or surgery-can improve long-term health outcomes in children and adults. The Farooqi lab and colleagues showed setmelanotide can manage obesity in patients < 6 years old.
doi.org/10.1016/S221...
doi.org/10.1016/S221...